Janus Kinase (JAK) · PROTEIN FAMILY · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Janus Kinase (JAK) shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P52333. Start with rheumatoid arthritis, then reuse UniProt P52333 as the stable protein anchor across project notes and exports.
Start with rheumatoid arthritis, then reuse UniProt P52333 as the stable protein anchor across project notes and exports.
Janus Kinase (JAK) shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with rheumatoid arthritis because it currently carries approved-linked support. Linked drugs include PEFICITINIB, TOFACITINIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTyrosine-protein kinase JAK3
Review this target as Janus Kinase (JAK), mapped to UniProt P52333. ChEMBL maps the protein component as Tyrosine-protein kinase JAK3. Sequence length is 1124 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Janus Kinase (JAK) as ChEMBL target CHEMBL2363062, mapped to UniProt P52333. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Janus Kinase (JAK) is the right protein anchor across sources, using UniProt P52333 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why rheumatoid arthritis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Janus Kinase (JAK) |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P52333 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tyrosine-protein kinase JAK3 |
| UniProt Accession | P52333 |
| Component Type | Protein |
| Sequence Length | 1124 aa |
Tyrosine-protein kinase JAK3
Review this target as Janus Kinase (JAK), mapped to UniProt P52333. ChEMBL maps the protein component as Tyrosine-protein kinase JAK3. Sequence length is 1124 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Janus Kinase (JAK) shows approved-linked disease relevance led by rheumatoid arthritis. 5 more disease programs remain visible in the same review block.
Start review with rheumatoid arthritis because it currently carries approved-linked support. Linked drugs include PEFICITINIB, TOFACITINIB CITRATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4764019 | 8.55 | IC50 | 2.8 | Preclinical |
| CHEMBL4742159 | 8.48 | IC50 | 3.3 | Preclinical |
| CHEMBL4575813 | 8.4 | IC50 | 4.0 | Preclinical |
| CHEMBL4740778 | 8.4 | IC50 | 4.0 | Preclinical |
| CHEMBL4093813 | 8.35 | IC50 | 4.5 | Preclinical |
| CHEMBL4777342 | 8.33 | IC50 | 4.7 | Preclinical |
| CHEMBL4594275 | 8.3 | IC50 | 5.0 | Clinical |
| CHEMBL4793262 | 8.3 | IC50 | 5.0 | Preclinical |
| CHEMBL4744172 | 8.28 | IC50 | 5.2 | Preclinical |
| CHEMBL1287853 | 8.22 | IC50 | 6.0 | Approved |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 27 | 71 | 6.6 |
| protein format | 9 | 4 | 8.2 |
| tissue-based format | 8 | 1 | 5.0 |
| assay format | 5 | 19 | 7.3 |